LFG
INBX icon

Larson Financial Group’s Inhibrx INBX Stock Holding History

Larson Financial Group’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-581
Closed -$9.1K – 2832
2024
Q3 		$9.1K Buy
+581
New +$8.16K ﹤0.01% 1510

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
SC
Slotnik Capital Dallas, Texas $342M AUM 105.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Larson Financial Group's INBX Position: Q4 2024 in Review

Larson Financial Group sold out of Inhibrx (INBX) in Q4 2024, closing a stake of 581 shares — an estimated $9.1K sold.

Larson Financial Group first reported a position in INBX in Q3 2024 and held it in 1 quarter. The position peaked at $9.1K in Q3 2024. 101 funds tracked by Wall St. Rank hold INBX as of Q4 2024.

  • Larson Financial Group reported no remaining Inhibrx position as of Q4 2024 after selling out during the quarter.
  • Larson Financial Group sold 581 Inhibrx shares in Q4 2024, an estimated $9.1K.
  • Larson Financial Group first reported a position in Inhibrx in Q3 2024 and held it in 1 quarter.
  • Larson Financial Group's Inhibrx position peaked at $9.1K in Q3 2024.
  • 101 funds tracked by Wall St. Rank held Inhibrx as of Q4 2024.

Based on Larson Financial Group's 13F filing for Q4 2024, filed 7 Feb 2025.